[{"AccountsPayableCurrent_0_Q1_USD":14405000.0,"AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_0_Q1_USD":-355000.0,"ShortTermInvestments_0_Q1_USD":365088000.0,"ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_1_Q1_USD":187600000.0,"InvestmentsFairValueDisclosure_0_Q1_USD":698456000.0,"RestrictedCashCurrent_0_Q1_USD":161000.0,"ProceedsFromSaleOfAvailableForSaleSecurities_1_Q1_USD":16600000.0,"AvailableForSaleSecuritiesGrossRealizedGainLossNet_1_Q1_USD":0.0,"AvailableForSaleSecuritiesAmortizedCost_0_Q1_USD":664226000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q1_USD":129000000.0,"AvailableForSaleSecurities_0_Q1_USD":663036000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q1_USD":-1349000.0,"InvestmentIncomeInterest_1_Q1_USD":2919000.0,"DepreciationDepletionAndAmortization_1_Q1_USD":2852000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q1_USD":-1398000.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-120423000.0,"OtherAccruedLiabilitiesCurrent_0_Q1_USD":13650000.0,"OtherAssetsNoncurrent_0_Q1_USD":4862000.0,"Goodwill_0_Q1_USD":44406000.0,"PaymentsToAcquireAvailableForSaleSecurities_1_Q1_USD":285229000.0,"OtherNonoperatingIncomeExpense_1_Q1_USD":-456000.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":20172000.0,"LongTermInvestments_0_Q1_USD":41711000.0,"RestrictedCashNoncurrent_0_Q1_USD":2608000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_1_Q1_USD":380000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_1_Q1_USD":-49000.0,"OperatingLeaseRightOfUseAsset_0_Q1_USD":35827000.0,"OperatingLeaseLiabilityNoncurrent_0_Q1_USD":34958000.0,"OperatingLeaseLiabilityCurrent_0_Q1_USD":7487000.0,"FinanceLeasePrincipalPayments_1_Q1_USD":33000.0,"EquitySecuritiesFvNiGainLoss_1_Q1_USD":7668000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q1_USD":24572000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1_Q1_USD":-623000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":-135285000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q1_USD":300959000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q1_USD":1773000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q1_USD":583000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":20157000.0,"AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0_Q1_USD":-1190000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_1_Q1_USD":299000.0,"ForeignCurrencyTransactionGainLossBeforeTax_1_Q1_USD":-474000.0,"ContractWithCustomerLiabilityCurrent_0_Q1_USD":145283000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q1_USD":36309000.0,"InventoryWorkInProcess_0_Q1_USD":8231000.0,"IncreaseDecreaseInInventories_1_Q1_USD":-149000.0,"Liabilities_0_Q1_USD":623994000.0,"InventoryNet_0_Q1_USD":11375000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1_Q1_USD":15096000.0,"IncreaseDecreaseInAccountsReceivable_1_Q1_USD":-3500000.0,"IncomeTaxExpenseBenefit_1_Q1_USD":409000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q1_USD":-118616000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-2.05,"DeferredTaxLiabilitiesNoncurrent_0_Q1_USD":33306000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":1233140000.0,"CommonStockValue_0_Q1_USD":59000.0,"CommonStockSharesIssued_0_Q1_shares":59488873.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":298190000.0,"AssetsCurrent_0_Q1_USD":894318000.0,"Assets_0_Q1_USD":1233140000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":8585289.0,"AdditionalPaidInCapital_0_Q1_USD":2162667000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":-1545000.0,"AccountsReceivableNetCurrent_0_Q1_USD":29327000.0,"CommonStockSharesOutstanding_0_Q1_shares":59488873.0,"InventoryFinishedGoods_0_Q1_USD":3144000.0,"LiabilitiesCurrent_0_Q1_USD":196858000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":-95125000.0,"SellingGeneralAndAdministrativeExpense_1_Q1_USD":47516000.0,"ResearchAndDevelopmentExpense_1_Q1_USD":112961000.0,"PreferredStockValue_0_Q1_USD":null,"PreferredStockSharesOutstanding_0_Q1_shares":0.0,"PreferredStockSharesAuthorized_0_Q1_shares":25000000.0,"OperatingIncomeLoss_1_Q1_USD":-120665000.0,"OperatingExpenses_1_Q1_USD":156974000.0,"CommonStockSharesAuthorized_0_Q1_shares":250000000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":55615000.0,"AccruedLiabilitiesCurrent_0_Q1_USD":67719000.0,"StockholdersEquity_0_Q1_USD":609146000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-1552035000.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":47596000.0,"ProfitLoss_1_Q1_USD":-119025000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q1_USD":64788000.0,"PaymentsToAcquirePropertyPlantAndEquipment_1_Q1_USD":14096000.0,"NetIncomeLoss_1_Q1_USD":-119025000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-95152000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":57995999.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1_Q1_USD":7397000.0,"Ticker":"RARE","CIK":"1515673","name":"ULTRAGENYX PHARMACEUTICAL INC.","OfficialName":"Ultragenyx Pharmaceutical Inc. Common Stock","form":"10-Q","period":"20200331","fy":"2020.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"5418950849.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200507"}]